Profile data is unavailable for this security.
About the company
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.
- Revenue in USD (TTM)0.00
- Net income in USD-171.36m
- Incorporated2019
- Employees51.00
- LocationMineralys Therapeutics Inc150 N. Radnor Chester Rd., Suite F200RADNOR 19087United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://mineralystx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Soleno Therapeutics Inc | 190.41m | 20.48m | 2.02bn | 182.00 | 252.77 | 4.54 | 88.05 | 10.59 | 0.1546 | 0.1546 | 3.61 | 8.61 | 0.4256 | -- | -- | 1,046,181.00 | 4.67 | -28.03 | 5.13 | -30.82 | 98.58 | -- | 10.97 | -130.73 | 5.55 | -- | 0.0997 | -- | -- | -- | 111.64 | -- | 59.83 | -- |
| Nuvation Bio Inc | 26.75m | -217.48m | 2.03bn | 291.00 | -- | 6.22 | -- | 75.75 | -0.6399 | -0.6399 | 0.0787 | 0.9508 | 0.0456 | -- | 6.34 | 121,581.80 | -37.08 | -33.42 | -41.58 | -34.49 | 54.26 | -- | -813.07 | -11,132.31 | 8.39 | -- | 0.3842 | -- | -- | -- | -649.24 | -- | -24.47 | -- |
| Stoke Therapeutics Inc | 205.63m | 40.57m | 2.08bn | 128.00 | 55.17 | 6.51 | 48.98 | 10.11 | 0.66 | 0.66 | 3.52 | 5.59 | 0.6293 | -- | 35.68 | 1,606,500.00 | 12.41 | -34.04 | 14.44 | -37.36 | -- | -- | 19.73 | -749.56 | -- | -- | 0.00 | -- | 316.34 | -- | 15.01 | -- | -34.11 | -- |
| Grail Inc | 147.17m | -408.35m | 2.15bn | 1.00k | -- | 0.8328 | -- | 14.59 | -11.18 | -11.18 | 4.01 | 63.92 | 0.0498 | -- | 7.62 | -- | -13.83 | -- | -14.21 | -- | 48.46 | -- | -277.47 | -- | -- | -- | -- | -- | 17.18 | -- | 79.85 | -- | -- | -- |
| Maze Therapeutics Inc | 0.00 | -101.46m | 2.19bn | 125.00 | -- | 5.78 | -- | -- | -2.68 | -2.68 | 0.00 | 7.89 | 0.00 | -- | -- | 0.00 | -41.05 | -- | -43.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 103.39 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 874.84m | 263.86m | 2.19bn | 435.00 | 7.27 | -- | 8.22 | 2.51 | 1.20 | 1.20 | 4.00 | -0.5593 | 1.74 | 2.83 | 9.41 | 2,011,120.00 | 52.53 | -18.78 | 81.42 | -25.41 | 97.82 | 97.60 | 30.16 | -23.15 | 2.03 | 4.99 | 1.34 | -- | 94.10 | 117.89 | 396.87 | -- | 36.86 | -- |
| Mineralys Therapeutics Inc | 0.00 | -171.36m | 2.32bn | 51.00 | -- | 4.01 | -- | -- | -2.96 | -2.96 | 0.00 | 7.30 | 0.00 | -- | -- | 0.00 | -39.48 | -- | -42.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -147.31 | -- | -- | -- |
| Dianthus Therapeutics Inc | 3.08m | -126.35m | 2.37bn | 78.00 | -- | 4.33 | -- | 768.79 | -3.48 | -3.48 | 0.085 | 12.75 | 0.0066 | -- | 0.8013 | 39,461.54 | -27.12 | -37.13 | -28.32 | -39.78 | -- | -- | -4,104.78 | -3,874.39 | -- | -- | 0.00 | -- | 120.63 | -- | -95.08 | -- | -49.06 | -- |
| Immunome Inc | 9.68m | -222.74m | 2.41bn | 118.00 | -- | 7.60 | -- | 249.18 | -2.95 | -2.95 | 0.122 | 2.88 | 0.0348 | -- | -- | 82,025.42 | -80.08 | -120.50 | -91.80 | -146.20 | -- | -- | -2,301.30 | -2,078.20 | -- | -- | 0.00 | -- | -35.50 | -- | -174.29 | -- | 196.63 | -- |
| Adaptive Biotechnologies Corp | 276.98m | -59.50m | 2.47bn | 619.00 | -- | 11.26 | -- | 8.91 | -0.3987 | -0.3987 | 1.79 | 1.42 | 0.5265 | 7.82 | 6.01 | -- | -11.30 | -22.45 | -13.86 | -25.94 | 74.24 | 66.23 | -21.47 | -88.21 | 3.23 | -24.47 | 0.3684 | -- | 54.77 | 23.00 | 62.69 | -- | -- | -- |
| Dyne Therapeutics Inc | 0.00 | -423.80m | 2.52bn | 240.00 | -- | 3.22 | -- | -- | -3.66 | -3.66 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -51.81 | -57.98 | -55.30 | -63.58 | -- | -- | -- | -- | -- | -- | 0.1254 | -- | -- | -- | -34.54 | -- | 7.60 | -- |
| Disc Medicine Inc | 0.00 | -212.18m | 2.54bn | 155.00 | -- | 3.41 | -- | -- | -5.98 | -5.98 | 0.00 | 19.53 | 0.00 | -- | -- | 0.00 | -32.55 | -30.94 | -34.12 | -32.93 | -- | -- | -- | -- | -- | -- | 0.0379 | -- | -- | -- | -94.03 | -- | -- | -- |
| Arcus Biosciences Inc | 247.00m | -353.00m | 2.55bn | 601.00 | -- | 4.04 | -- | 10.34 | -3.30 | -3.30 | 2.30 | 5.04 | 0.2158 | -- | 12.05 | 410,981.70 | -30.84 | -18.85 | -38.54 | -22.29 | -- | -- | -142.92 | -103.61 | -- | -- | 0.1356 | -- | -4.26 | 26.08 | -24.73 | -- | -8.12 | -- |
| Wave Life Sciences Ltd | 42.73m | -204.38m | 2.62bn | 317.00 | -- | 5.04 | -- | 61.38 | -1.21 | -1.21 | 0.2534 | 2.80 | 0.0863 | -- | 31.67 | 134,785.50 | -41.26 | -44.67 | -52.09 | -71.58 | -- | -- | -478.33 | -208.12 | -- | -- | 0.00 | -- | -60.55 | 16.31 | -110.68 | -- | -11.71 | -- |
Data as of Mar 02 2026. Currency figures normalised to Mineralys Therapeutics Inc's reporting currency: US Dollar USD
41.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 19 Feb 2026 | 7.32m | 9.62% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 4.21m | 5.53% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.77m | 4.95% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.18m | 4.19% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.92m | 3.83% |
| Caligan Partners LPas of 31 Dec 2025 | 2.77m | 3.64% |
| HBM Partners AG (Investment Management)as of 30 Sep 2024 | 2.25m | 2.95% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 1.79m | 2.35% |
| Laurion Capital Management LPas of 31 Dec 2025 | 1.71m | 2.25% |
| Holocene Advisors, LPas of 31 Dec 2025 | 1.60m | 2.11% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
